Ameriprise Financial Inc. Purchases 18,412 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Ameriprise Financial Inc. boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 205,173 shares of the company's stock after purchasing an additional 18,412 shares during the quarter. Ameriprise Financial Inc. owned about 0.24% of CRISPR Therapeutics worth $8,072,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. ARK Investment Management LLC boosted its holdings in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after buying an additional 1,474,439 shares during the period. Capital International Investors lifted its position in CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock worth $344,145,000 after acquiring an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after acquiring an additional 1,074,238 shares during the period. Vanguard Group Inc. grew its position in shares of CRISPR Therapeutics by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after purchasing an additional 10,579 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of CRISPR Therapeutics by 14.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 947,301 shares of the company's stock worth $37,283,000 after purchasing an additional 122,695 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $0.67 during midday trading on Friday, hitting $36.86. 1,256,881 shares of the company traded hands, compared to its average volume of 1,686,719. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of -8.43 and a beta of 1.88. The firm's fifty day moving average price is $37.05 and its 200-day moving average price is $41.94.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter last year, the company earned ($1.43) EPS. CRISPR Therapeutics's quarterly revenue was up 71.6% on a year-over-year basis. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Greene purchased 7,000 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 14,021 shares of company stock worth $594,771. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Barclays decreased their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Stifel Nicolaus dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. The Goldman Sachs Group dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reissued a "buy" rating and set a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.